版本:
中国

BRIEF-Five Prime Therapeutics announces completion of enrollment for the phase 2 of the ongoing trial of Cabiralizumab

April 10 Five Prime Therapeutics Inc:

* Five Prime Therapeutics announces completion of enrollment for the phase 2 part of the ongoing trial of cabiralizumab for the treatment of pigmented villonodular synovitis (PVNS)

* Five Prime Therapeutics Inc - Five Prime plans to seek regulatory feedback on design of a pivotal trial

* Five Prime Therapeutics - plans to present initial data from phase 2 part of trial at 2017 American Society Of Clinical Oncology (ASCO) annual meeting Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐